Abbvie Gets FDA Approval for Blood Cancer Drug
Abbvie Receives FDA Approval for Rare Blood Cancer Treatment
Abbvie announced that the U.S. Food and Drug Administration (FDA) has approved Decnupaz for the treatment of adults with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), an ultra-rare and aggressive form of leukemia.
Clinical Trial Data
The approval is based on a Phase 1/2 trial evaluating the safety and efficacy of Decnupaz. Newly diagnosed patients achieved a composite complete response rate of 69.7%.
About the Disease
BPDCN typically affects adult men between ages 60 and 70, often presenting as skin lesions. It can rapidly spread to bone marrow, lymph nodes, and the central nervous system. Relapse is common even after intensive chemotherapy.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.